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Herpes zoster can be serious or incapacitating, particularly in patients whose immune
system is compromised by a disease or treatment. Immunomodulating drugs can
increase the risk of infection. Well-established risk factors include advanced age and
glucocorticoid therapy. The data are somewhat conflicting for medications such as
methotrexate, tofacitinib, TNFα antagonists (infliximab, adalimumab, etanercept,
certolizumab, and golimumab), abatacept, tocilizumab, and rituximab. Nevertheless,
the risk of herpes zoster is increased in patients taking biological agents, because of
the underlying diseases and/or effects of the drugs. A live attenuated herpes zoster
vaccine has been proven effective and safe in immunocompetent individuals. At
present, however, it is not recommended for patients with immunodeficiencies,
including those taking biological drugs, as no studies have assessed its risk/benefit
ratio in this population. This situation may change in the near future, as recent data
support the effectiveness and safety of the herpes zoster vaccine in patients who take
biotherapies or have other causes of immunodeficiency. Alternative approaches
designed to protect these patients from herpes zoster and its complications are also
under evaluation. There is a need to define the indications of the herpes zoster vaccine
in terms of the target population, timing, modalities, and frequency, according to the
underlying chronic systemic disease, age group, varicella-zoster virus status, and
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